

#### Abstract

Ageing is the greatest global healthcare challenge, as it underlies age-related functional decline and is the primary risk factor for a range of common diseases, including neurodegenerative conditions such as Alzheimer's disease (AD). However, the molecular mechanisms defining chronological age versus biological age, and how these underlie AD pathogenesis, are not well understood. The objective of this study was to integrate common human genetic variation associated with human lifespan or AD from Genome-Wide Association Studies (GWAS) with co-expression networks altered with age in the central nervous system, to gain insights into the biological processes which connect ageing with AD and lifespan. Initially, we identified common genetic variation in the human population associated with lifespan and AD by performing a gene-based association study using GWAS data. We also identified preserved co-expression networks associated with age in the brains of C57BL/6J mice from bulk and single-cell RNA-sequencing (RNA-seq) data, and in the brains of humans from bulk RNA-seq data. We then intersected the human gene-level common variation with these co-expression networks, representing the different cell types and processes of the brain. We found that genetic variation associated with AD was enriched in both microglial and oligodendrocytic bulk RNA-seq gene networks, which show increased expression with ageing in the human hippocampus, in contrast to synaptic networks which decreased with age. Further, longevity-associated genetic variation was modestly enriched in a single-cell gene network expressed by homeostatic microglia. Finally, we performed a transcriptome-wide association study (TWAS), to identify and confirm new risk genes associated with ageing that show variant-dependent changes in gene expression. In addition to validating known 51 ageing-related genes such as *APOE* and *FOXO3*, we found that Caspase 8 (CASP8)

and APOC1 show genetic variation associated with longevity. We observed that variants contributing to ageing and AD balance different aspects of microglial function suggesting that ageing-related processes affect multiple cell types in the brain. Specifically, changes in homeostatic microglia are associated with lifespan, and allele-dependent expression changes in age-related genes control microglial activation and myelination influencing the risk of developing AD. We identified putative molecular drivers of these genetic networks, as well as module genes whose expression in relevant human tissues are significantly associated with AD-risk or longevity, and may drive "inflammageing." Our study also shows allele-dependent expression changes with ageing for genes classically involved in neurodegeneration, 62 including MAPT and HTT, and demonstrates that PSEN1 is a prominent member/hub of an age-dependent expression network. In conclusion, this work provides new insights into cellular processes associated with ageing in the brain, and how these may contribute to the resilience of the brain against ageing or AD-risk. Our findings have important implications for developing markers indicating the physiological age and pre-pathological state of the brain, and provide new targets for therapeutic intervention.

### Introduction

Biological ageing is the decline of adult tissue function following development. The mammalian central nervous system (CNS), shows various impairments in function with age, such as impaired spatial memory, episodic memory, and executive 75 function<sup>1–3</sup>. This decline in function has been linked to cellular changes in different brain regions, including modification of synaptic connections, and inflammatory 77 changes<sup>3,4</sup>. Ageing is considered the primary risk factor for a number of neurodegenerative conditions including Alzheimer's disease (AD), however the 79 molecular mechanisms linking ageing and AD are not well understood<sup>1,5,6</sup>. Therefore, understanding the mechanisms of biological ageing may not only facilitate combatting the widespread and growing morbidity caused by age-related CNS decline, but also provide insights into the onset and progression of age-dependent diseases, such as AD.

Model organisms have revealed important insights into genetic pathways which can dramatically alter organismal lifespan and healthspan when manipulated. Manipulating these pathways in humans is not trivial, but understanding the causes of ageing in specific tissues, such as the CNS, may enable more directed treatments with 89 less side-effects<sup>3,5,7–9</sup>. Gene expression changes with ageing have been studied comprehensively in different tissues, including the brain. While these studies shed light on age-associated transcriptional changes, it is not clear which of the many altered pathways drive age-associated changes, and thus which pathways should be targeted by anti-ageing therapies that may also be capable of slowing age-dependent CNS-disorders. The use of genome-wide association studies (GWAS) has advanced our ability to identify genetic variation associated with human ageing and age-related

diseases, with the identification of genes such as APOE and FOXO3 which are 97 associated with ageing in some populations<sup>10,11</sup>. Genetic variation in these genes may underlie some of the differences in ageing between people that are long-lived versus those that live an average lifespan. However, these genes are often multi-functional, so how genetic variation modulates biological pathways of ageing are not clear.

Ageing affects all cell types in the brain from neurons to microglia and the supporting vasculature. Emerging data are also revealing prominent disruption of myelin occurs with ageing. Myelin is a layered lipid-rich membrane produced by oligodendrocytes which ensheaths neuronal axons, providing metabolic support and enabling fast propagation of action potentials. In mammals, significant age-related changes are observed in highly myelinated areas of the brain, known as white matter, starting from around 50 years of age in humans. These include hyperintensities seen by magnetic resonance imaging (MRI), as well as myelin outfolding and accumulation of 110 multilamellar fragments seen by electron microscopy<sup>12–14</sup>. Myelin regeneration or remyelination occurs during ageing and injury. Indeed, axonal function can be restored via the proliferation and differentiation of oligodendrocyte precursor cells 113 into mature oligodendrocytes that lay down new myelin at sites of lesions $14,15$ . However, remyelination becomes impaired in the aged brain. Microglia are thought to play an important protective role in the remyelination process, by clearing degenerated myelin that accumulates during ageing and disease through phagocytosis, and by secretion of growth factors and cytokines to support oligodendrocyte 118 maturation, and to remodel the extracellular matrix<sup>13,14,16,17</sup>. Recent work has shown that myelin disruption with ageing in rodents can drive accumulation of amyloid 120 plaques, by entangling microglia, potentially contributing to AD pathogenesis<sup>18</sup>.

However, little is known about the genetic and molecular mechanisms leading to disruption of myelin with ageing, or its importance in determining healthspan of the brain and AD risk.

To better understand the age-dependent processes within the CNS that contribute to lifespan and AD pathogenesis, we used a four-step approach to identify biological pathways that are dysregulated with age, and are enriched for genes associated with longevity or AD risk. Firstly, we identified common human genetic variation associated with ageing or AD at the gene-based level by aggregating individual SNPs' significance and by testing the joint association of all SNPs in the gene accounting for linkage disequilibrium (LD) and number of SNPs per gene. Secondly, we overlaid this human genetic variation onto age-associated gene co-expression networks, generated from bulk and single-cell RNA-sequencing (scRNA-seq)-based transcriptomic profiling of the mouse hippocampus, a region which is thought to be central to both 135 age-related cognitive decline and  $AD^{3,19}$ . Thirdly, we tested for an enrichment of gene variants associated with ageing and AD in different co-expression networks which are dysregulated with age in the mouse and human hippocampus. We found a significant enrichment of gene variants associated with AD in human microglial and oligodendrocytic networks, whose expression was also significantly increased with age. Assessment of changes in co-expression modules with ageing at the single-cell level in microglia identified stark similarities to changes in young mice treated with cuprizone to induce demyelination, indicating that age-related demyelination may provide a link between these two AD-associated processes. Furthermore, we saw a modest but significant enrichment of genes associated with ageing in humans in a single-cell co-expression network, highly expressed by homeostatic microglia, which



#### Results

# Identification of genes harbouring common genetic variation associated with longevity and AD

We initially identified genes harbouring common genetic variants associated with lifespan to capture each gene's collective SNPs, even if a single SNP does not reach genome-wide significance, by performing a gene-based analysis with the summary statistics from a meta-analysis combining three different GWAS associated with 162 lifespan<sup>10</sup>. Our gene-based analysis showed *APOC1* ( $P_{FDR} = 2.49e-63$ ), and *APOE* 163 ( $P_{FDR} = 1.95e-46$ ), were the strongest genes associated with the measures of lifespan 164 (top genes associated with lifespan are given in Supplementary Table 1,  $P_{FDR}$  < 0.01). The results of a similar gene-based analysis on the data from the International 166 Genomics of Alzheimer's Projects  $(IGAP)^{21}$  to identify genes harbouring common genetic variation associated with AD risk are given in Supplementary Table 2 (top 168 genes associated with AD,  $P_{FDR}$  < 0.01).

# Transcriptional networks of oligodendrocytic and microglial genes are associated with age in the mouse hippocampus

We then sought to gain insights into which biological pathways contained the genes associated with longevity and AD (Supplementary Tables 1 and 2), while determining how these pathways are affected by ageing. To determine transcriptomic changes associated with ageing at the systems level, we performed weighted gene co-176 expression analysis  $(WGCNA)^{22}$ , with an optimization for constructing more 177 biologically meaningful co-expression networks<sup>23</sup>, to group genes which were co-178 expressed in the hippocampi of C57BL/6J wild-type mice at 2-18 months-of-age<sup>24</sup>. We identified eight co-expression modules whose expression was significantly

associated with age (Pearson's product-moment correlation with age, here and 181 thereafter,  $R^2 > 0.4$ , p < 0.01; Fig. 1a), from more than 20 modules. Using cell-type enrichment analysis, we determined that the module with strongest correlation to age  $(R^2 = 0.93, p \le 0.001)$ , was heavily enriched for microglial genes (microglial module). 184 A second module which significantly correlated with age ( $R^2 = 0.54$ ,  $p < 0.01$ ), was heavily enriched for oligodendrocytic genes (mouse oligodendrocytic module) (Fig. 1b). Corresponding with their cell-type annotations, the mouse microglial module was significantly enriched for biological annotations associated with innate immunity, while the oligodendrocytic module was enriched for myelination and axon ensheathment (Fig. 1c, d).

Genes with the highest connectivity to other genes within a co-expression module are known as hub genes, and are postulated to drive the response of the entire 193 network<sup>25,26</sup>. The mouse microglial module contained as hub genes,  $\pi$ *l* 133, *Erbin, Sspn*, *Neatl*, and *Zc3havl*, and also contained the canonical microglial genes *Trem2* and *Apoe* (Fig. 1c). The oligodendrocytic module included the hub genes: Mobp, Tmem88b, Plp1, Plekhh1, Plekhb1, Galnt6, Bcas1 and Prr18 (Fig. 1d). Interestingly, while analysis of single-cell RNA-seq data determined that 14 of the 15 most-connected genes in the bulk microglial module were also detected by scRNA-seq of 199 the mouse hippocampus at 3 and 24 months-of-age<sup>27</sup>, 8 of these genes were predominantly detected in oligodendrocytes, where they all showed elevated expression with age (Supplementary Fig. 1). Overall, these scRNA-seq findings indicate that while the microglial module is significantly enriched for microglial 203 genes such as *Apoe* and *Trem2*, its hub genes are contributed by other cell types, disproportionately oligodendrocytes, including genes coding for signalling molecules

known to affect microglial function such as the interleukin Il33 and complement 206 component  $C4b^{28-30}$ . This suggests age-related signalling from oligodendrocytes may trigger microglial activation in the aged hippocampus.

Since transcriptional changes in mice can be affected by many co-variates, such as mouse strain, husbandry conditions, diet, and technical variation due to RNA preparation, RNA-seq protocols and analysis pipeline, we then tested whether the age-dependent co-expression networks were preserved in other bulk RNA-seq datasets of wild-type mouse hippocampus or cortex at various ages from 13-126-weeks of age 214 from three other labs, processed via a variety of pipelines<sup>31–33</sup>. We saw strong preservation of both the microglial and oligodendrocytic modules, with respect to gene expression connectivity and correlation to age in the different datasets (strong preservation, z.summary > 10 for co-expression patterns between module genes; 218 microglial module  $R^2$  with age >0.93 and oligodendrocytic module  $R^2 > 0.58$  against two further query datasets; Supplementary Fig. 2). This provides evidence that the age-dependent co-expression networks are preserved between different mice, labs, and sequencing experiments.

# Single-cell RNA-seq changes of age-dependent gene expression

Given that recent scRNA-seq studies have revealed that microglia respond heterogeneously to various challenges, we sought to determine age-dependent co-expression networks at the single-cell level, using scRNA-seq data generated from microglia isolated from male and female wild-type mice hippocampi at 3, 6, 12, and 21 months-of-age (2 mice of each sex/age, pooled prior to sequencing) (data from 229 Sala Frigerio et al., 2019<sup>34</sup>). Previous analysis of this data identified 6 microglial

subpopulations: homeostatic microglia 1 and 2 (HM1 and HM2), which highly express genes associated with microglial homeostatic functions; cycling proliferating microglia (CPM), which express genes involved in the cell cycle; activated response microglia (ARM); interferon response microglia (IRM); and transiting microglia (TRM) which may be an intermediate state between homeostatic microglia and ARM<sup>34</sup>. We identified eight co-expression modules expressed by distinct microglial sub-populations in the mouse hippocampus (Fig. 2a). To reliably assess the age-related changes in expression of these modules in more replicates than those available in scRNA-seq data, we assessed these modules' dysregulation (using the mean expression of the core 100 genes with the highest connectivity) between independent replicates of microglia isolated from wild-type mice hippocampi at 2 and 16-18 241 months-of-age, and profiled by bulk RNA-seq (data from O'Neil *et al.*, 2018<sup>35</sup>).

Six gene modules exhibited altered expression with age. A module of genes representing activated microglia exhibited strikingly increased expression with age 245 (ARM-associated module,  $p = 1.2e-3$ , Student's *t*-test; Fig. 2a, b, c, d). This module was predominantly expressed by the ARM subpopulation of activated microglia, which are synonymous with the disease-associated microglia (DAM) subpopulations 248 seen in AD mouse models<sup>34,36</sup>. Interestingly, this module's hub genes (Spp1, Clec7a, 249 Lilrb4a; Fig. 3a) have been reported to mark microglia scavenging fragmented myelin 250 in the corpus callosum, which also become more numerous with ageing<sup>13</sup>. This module is significantly enriched for biological annotations related to phagocytosis, cytokine production, and TYROBP signalling (Supplementary Fig. 3a). Another gene module consisting of interferon-stimulated genes was also increased with ageing 254 (Interferon module,  $p = 8.0e-3$ , Student's *t*-test; Fig. 2f, and Fig. 3b), and was

associated with a distinct subpopulation of interferon responsive microglia, IRM, so was named the interferon module. This module is significantly enriched for biological annotations related to the interferon response (Supplementary Fig. 3b). A further module containing ribosomal genes, was more modestly increased with ageing 259 (ribosomal module;  $p = 3.0e-2$ , Student's *t*-test, Fig. 2h and Supplementary Fig. 3). In contrast, a module strongly associated with a homeostatic subcluster, HM2, was 261 decreased during ageing (HM2-associated module,  $p = 1.4e-5$ , Student's *t*-test; Fig. 2j and Fig. 3c). While a module associated with a different homeostatic subpopulation of 263 microglia, HM1 (HM1-associated module,  $p = 8.7e-3$ , Student's *t*-test; Fig. 21), and a 264 module associated with TGF- $\beta$  signalling (TGF- $\beta$  module, p = 4.0e-4, Student's *t*-test; Fig. 2n and Supplementary Fig. 3), were more modestly decreased during ageing. Finally, modules containing phagocytosis and lysosomal genes (phagolysosomal module; Fig. 3d and Supplementary Fig. 3), or associated with the CPM cluster 268 (CPM-associated module), were not significantly altered during ageing ( $p > 0.05$ , 269 Student's *t*-test).

To gain further insights into how these modules relate to microglial activation, we used semi-supervised Pseudotime analysis to order cells by their expression of genes 273 which nominally significantly differ  $(p < 0.05)$  between subpopulations (Fig. 2b), 274 using Monocle  $2^{37,38}$ . We saw that the HM1 microglial subpopulation could be considered as the root state, and then the ARM and IRM populations acted as the endpoint of distinct activation trajectories, with HM2 and TRM as intermediate states. We saw that the ARM trajectory was defined by increased expression of the ARM-associated module of genes, although some cells in the IRM trajectory also expressed this gene module (Fig. 2c). The ribosomal module was also upregulated along the ARM trajectory (Fig. 2g). While the IRM trajectory was defined by increased expression of the interferon module (Fig. 2e). In contrast, expression of the HM1- /HM2-associated, and TGF-β-associated modules was highest in the root homeostatic state and decreased along both activation trajectories (Fig. 2i, k, m). Collectively these data show that microglial transcription programs associated with states considered to be activated are increased with age in the mouse hippocampus, and transcriptional signatures associated with homeostatic functions are decreased with age.

# Single-cell RNA-seq signatures of microglia associated with ageing resemble the

### changes seen with demyelination

Due to the enrichment of oligodendrocytic hub genes in our bulk microglial module, we then sought to gain further insight into whether the microglial responses during ageing seen in our single-cell analysis may be influenced by interactions with oligodendrocytes. Demyelination is a major feature of oligodendrocyte ageing in the 294 mouse hippocampus<sup>39</sup>. Therefore, we examined how these age-dependent scRNA-seq modules were affected when microglia were exposed to demyelination in young mice, 296 following feeding with cuprizone (data from  $Ref<sup>40</sup>$ ). Interestingly, we found that the co-expression of genes within our age-associated microglial modules (Fig. 2 and 3) were strongly preserved in young mice fed a demyelinating diet (Fig. 4a), indicating that these genes were also co-expressed in these mice exhibiting demyelination. Looking again at our age-dependent modules of interest (Fig. 2 and 3), we found that the average expression of their 100 most connected genes showed the same change with demyelination as they showed with ageing. The ARM-associated module (ARM 303 population) was increased after both 5-weeks ( $p = 6.7e-5$ , Dunnett's test), and 12-304 weeks ( $p = 9.3e-6$ , Dunnett's test) of a demyelinating cuprizone diet, mirroring the

305 changes seen with ageing (Fig. 4b). The average expression of core interferon-306 response module genes was increased following 5-weeks ( $p = 4.0e-3$ , Dunnett's test) 307 of a demyelinating cuprizone diet, as we saw during ageing, although this subsided 308 after 12-weeks of the cuprizone diet ( $p = 2.4e-1$ , Dunnett's test; Fig. 4c). While the 309 ribosomal module was more modestly elevated following 5- and 12-weeks on the 310 cuprizone diet (5-weeks:  $p = 2.9e-3$ ; 12-weeks:  $p = 2.6e-2$ ; Dunnett's tests; Fig. 4d). 311 In contrast, the average expression of core genes in the HM2-associated, HM1- 312 associated, and TGF- $\beta$  modules were decreased after both 5-weeks (HM2,  $p = 1.3e-2$ ; 313 HM1,  $p = 3.4e-2$ ; TGF- $\beta$ ,  $p = 1.2e-3$ ; Dunnett's tests) and 12-weeks (HM2,  $p = 2.9e-$ 314 4; HM1,  $p = 7.8e-3$ ; TGF- $\beta$ ,  $p = 6.0e-4$ ; Dunnett's tests) (Fig. 4e, f, g) of a 315 demyelinating cuprizone diet, mirroring the repression of these modules during 316 ageing (Fig. 2). Overall, these data provide evidence that the transcriptional 317 programmes we identified were similarly changed in microglia during ageing and in 318 response to the breakdown of myelin in young mice.

319

# 320 Transcriptional networks of oligodendrocytic and microglial genes are 321 associated with age in the human hippocampus

322 As ageing in mice may not reflect ageing in humans<sup>41,42</sup>, we then performed a 323 comparable analysis of bulk RNA-seq data from the non-diseased hippocampi of 196 324 cognitively normal individuals from the GTEx consortium<sup>43</sup>. This analysis produced 325 several co-expression modules significantly correlated to age (Fig. 5a). Strikingly, the 326 module most correlated to age was enriched for microglial genes ( $\mathbb{R}^2 = 0.73$ , p < 327 0.001; Hu Microglial module), as was the case in mice, with genes such as TYROBP, 328 SYK and CD53 presenting as hub genes (Fig. 5a, b). Additionally, expression of an 329 oligodendrocytic gene enriched module ( $R^2 = 0.58$ , p < 0.001; Hu Oligodendrocyte

module) was also significantly positively associated with age, with genes such as ENPP2, CNTN2, PSEN1, SLC44A1 and CYP27A1 presenting as hub genes (Fig. 5a, c). However, despite this broad inter-species similarity, there were differences in the gene constituents of these modules compared to their mouse counterparts, as the human and mouse microglial, and oligodendrocytic co-expression modules showed only moderate preservation of their gene co-expression patterns in the mouse data (Fig. 5d). Correspondingly, 42 genes in the human microglial module have 337 orthologues in the mouse microglial module ( $p = 3.4e-26$  overlap, Fisher's Exact Test), and 90 genes in the human oligodendrocyte module have orthologues in the 339 mouse oligodendrocyte module ( $p = 1.6e-75$  overlap, Fisher's Exact Test). Genes 340 unique to the mouse age-dependent microglial network included  $B2m$ ,  $Cst7$ ,  $Pik3cg$ 341 and Ccl4, and also Il33 which is expressed mostly by oligodendrocytes and is part of the age-dependent module because it shows expression changes very similar to the microglial genes. In contrast, genes unique to the human age-dependent microglial network included ABI3, ALOX5AP, C1QA-C, CD68, CD74, CSF1R, FCER1G, ITGAM, MRC1, MS4A6A, P2RY12, RUNX1, SAMSN1, SPI1, STAT6, SYK and TYROBP. To gain further insights into how the age-dependent microglial response is different between humans and mice, we investigated biological annotations associated with the age-dependent genes unique to either mouse or human using the Gprofiler2 R 349 package<sup>44</sup>. The age-dependent genes unique to mouse were associated with antigen presentation involving the major histocompatibility complex (MHC)(Supplementary Fig. 4a). Whereas age-dependent genes unique to humans were associated with leukocyte activation, cytokine production and T cell activation (Supplementary Fig. 4b). Therefore, the human and mouse age-related gene networks are overlapping, but each organism has its own distinct components of the network and so some of the

human age-related processes which modulate AD risk and longevity in humans are not seen in mice.

#### Microglial and oligodendrocytic gene networks are enriched for AD risk genes

Our previous study testing for enrichment of common human gene variants in a co-expression network associated with amyloid plaques demonstrated that genetic risk for AD is substantially encoded by genes expressed during the response of microglia to these plaques<sup>24</sup>. Therefore, to investigate whether our age-dependent co-expression networks were connected to AD, we tested the mouse and human age-dependent bulk RNA-seq co-expression networks for enrichment of genes, or mouse orthologues of human genes, significantly associated with AD (top genes associated with AD are 366 given in Supplementary Table 2,  $P_{FDR}$  < 0.01). Enrichment analyses were performed by comparing the number of overlapping genes in our gene-sets with randomly sampled gene-sets matched for LD, gene size and the number of genes in a set. We saw no significant enrichment of common human AD-associated genes in the age-dependent mouse networks from bulk RNA-seq (Fig. 1 and Table 1). In contrast, we saw a significant enrichment of overlapping genes associated with AD in both the age-dependent human microglial network (enrichment p = 1e-05, bootstrap-based 373 test) and oligodendrocytic network (enrichment  $p = 0.033$ , bootstrap-based test) (Fig. 5b, c, and Table 1). The genes driving the enrichment (gene-based p-values < 0.01) of the microglial module are known AD-associated risk genes (CD33, GAL3ST4, HLA-DRB1, INPP5D, MS4A4A, SPI1, TREM2), and putative risk genes (ITGAM, LAPTM5 377 and  $LILRB4)^{24}$  (Fig. 5 and Supplementary Table 3). We also observed genes with gene-based p-values < 0.01 not before linked to AD, which are likely to contribute to AD risk when combined with their co-expression with other genes enriched for AD

risk, namely, APOC2, ARHGAP45, ATP8B4, CMTM7, COX7A1, DOCK3, MARCO,

381 MLPH, NOP2, PCED1B and TMC8 (Table 1; Supplementary Table 3). Therefore, the age-dependent microglial genetic network identified here both highlights a role for microglial-associated age-related changes in determining AD risk, and predicts new putative risk genes for AD.

None of the genes within the human oligodendrocytic module had previously been identified as GWAS hits for AD risk. Nevertheless, CLASRP meets genome-wide 388 significance in our analysis ( $P_{FDR} = 1.50e-10$ ), highlighting the benefit of our gene-based association analysis, and indicating a potential oligodendrocytic role for this gene in the human hippocampus. CLASRP is in the same region as APOE, but is included here as a gene of interest because it shows age-dependent expression changes. Moreover, the large number of co-expressed genes (29 genes) containing 393 genetic variation associated with AD below our threshold (gene-based  $p < 0.01$ ; Table 1; Supplementary Table 4), indicates that genetic variation which influences myelination during ageing may play a role in AD pathogenesis.

# A homeostatic microglial gene network is enriched with common gene variants associated with longevity

To determine which specific microglial transcriptional programs are particularly associated with AD and longevity, we repeated our assessment of enrichment for common genetic variation associated with these traits, using modules from our scRNA-seq analysis (Fig. 3). Comparing the number of overlapping genes from our modules to bootstrapped modules containing the same number of genes randomly selected from those reliably detected from this dataset (to account for the relative

enrichment of microglia-expressed genes with these traits), we observed a trend for enrichment of genes associated with AD within the genes present in the ARM- and phagolysosomal-associated modules (Fig. 3 and Table 1; Supplementary Tables 5 and 6). Furthermore, our analysis suggests that the HM2-associated module is significantly, but modestly, enriched for genetic variation associated with longevity 410 (enrichment  $p = 0.032$ , bootstrap-based test) (Table 2; Supplementary Table 7). This 411 module contains the mouse orthologue of *FOXO3* and *ATXN2*, which have previously 412 been linked to longevity by GWAS studies, as well as cognitive decline (FOXO3), 413 and late-onset Parkinson's disease and Spinocerebellar Ataxia  $2^{10,45,46}$ . This homeostatic microglial module also includes the mouse orthologue of CASP8, which acts as a molecular switch to control cell death via apoptosis, necroptosis and 416 pyroptosis<sup>47</sup>. Importantly, the longevity-associated role of these genes has not previously been linked to microglia.

Transcriptome-wide association study highlights the new genes associated with AD risk and genes expressed by homeostatic microglia that are associated with longevity

To investigate genetic variation associated with longevity using an independent approach, we performed a TWAS, to identify genes in which a change in expression is associated with genetic contribution to longevity. Data are not available to perform this analysis with microglia, but since peripheral monocytes differentiate into microglia-like macrophages within the CNS, we used expression data from naïve 427 (CD14) and induced monocytes (LPS and IFN-gamma) from the Fairfax dataset<sup>48</sup>, as 428 previously performed for  $AD^{20}$ . In addition, we used expression data from the Genotype-Tissue Expression (GTEx) Project including the brain and hippocampus

430  $\frac{43,49}{ }$ , whole blood from the young Finns study (YFS)<sup>50</sup>, and the Netherlands twin 431 register peripheral blood  $(NTR)^{51}$ . These datasets include sorted CD14+ve myeloid 432 cells, whole blood, and hippocampus, which can shed light on myeloid cell 433 transcription. Using the AD TWAS, this approach confirmed the importance of 434 known AD risk genes such as APOE, BIN1, CD33, CR1, MS4A4A, OAS1 and SPI1 435 (extracted from the Supplementary data of Harwood *et al.*  $(2021)^{20}$ , and summarised 436 in Supplementary Table 8). Furthermore, this approach also identified new risk genes 437 not previously associated with AD, such as  $GEMIN7$  (frontal cortex,  $p = 2.17e-11$ , Z 438 = 6.69) and MTCH2 (frontal cortex,  $p = 2.44e-10$ ,  $Z = -6.33$ ) (extracted from the 439 Supplementary data of Harwood *et al.*  $(2021)^{20}$  and summarised in Supplementary 440 Table 8). GEMIN7 is in the same region as APOE, but is included here as a gene of 441 interest because it shows transcription-dependent association. Using the longevity 442 GWAS, we noted known genes showing variation associated with longevity including 443 FOXO3, where reduced FOXO3 expression was significantly associated with 444 longevity in whole blood (Fig. 6 and Supplementary Fig. 5). Additionally, we 445 identified several genes associated with altered expression and longevity, such as 446 ADD1, a cytoskeletal protein which achieved genome-wide significance in the CD14- 447 positive monocyte cell dataset, with increased expression being linked to longevity 448 (Fig. 6 and Supplementary Fig. 5). CASP8 also achieved genome-wide significance in 449 cortical tissue (frontal cortex,  $p = 3.71e-08$ ,  $Z = -5.50$ ; Fig. 6 and Supplementary 450 Table 9), and blood, with decreased expression linked to longevity (Supplementary 451 Fig. 5). Cathepsin S (CTSS) was also significant in the putamen, with increased 452 expression linked to longevity (Supplementary Fig. 5 and Supplementary Table 9). 453 This approach has highlighted new genes associated with longevity ( $p < 0.01$  and  $Z >$ 454 3.0 or  $\le$  -3.0), of which around half are thought to interact via Ingenuity pathway

455 analysis including APOE, CASP8, CTSB, CTSH, CTSS, LIPA, LPL, NPC1 and TUFM (Fig. 7 and Supplementary Table 9). Given that FOXO3, ADD1 and CASP8 are expressed by homeostatic microglia, and that genetic variation associated with longevity is enriched in genes expressed by homeostatic microglia, our collective data suggest a model whereby genes associated with longevity are involved in the homeostatic functions of microglia, and perhaps other innate immune cells. If these innate immune cells escape this state of homeostasis by activating stimuli such as amyloid pathology and age-dependent myelin fragmentation, then genes associated with AD determine how microglia are activated and how they respond to these large disturbances in homeostasis (Fig. 8).

### Discussion

# Human common gene-level variation associated with AD is enriched in age-

### dependent oligodendrocytic and microglial co-expression networks

Human ageing and AD are so entwined due to numerous interconnected co-morbidities, such as vascular disease, and the long pre-symptomatic period of AD highlights the challenge of studying each phenomenon independently. A clear clue that links ageing and AD is that traditional GWAS have repeatedly demonstrated that *APOE* is the top genetic risk factor contributing to both late-onset  $AD^{21}$  and 474 longevity<sup>10,11</sup>, with the  $\epsilon$ 4 isoform being detrimental in both contexts, showing the 475 highest risk for AD (with earlier age of onset among the late-onset AD cases)<sup>52</sup>, and the lowest odds for longevity. Additionally, longevity shows a significant negative 477 genetic correlation with  $AD^{10}$ . However, the molecular mechanisms linking AD and ageing are poorly understood. To gain new insights into mechanisms linking ageing and AD, we have combined genetic association in human GWAS data with transcriptomic analyses of ageing in the human and mouse hippocampus, aiming to identify biological pathways and cell types which are both altered during ageing, and associated with longevity and/or AD-risk. We show that the expression of separate gene modules associated with microglia and oligodendrocytes are strongly positively correlated to age in both species. These age-dependent microglial and oligodendrocytic co-expression networks in mice show modest preservation in humans. Notably, only the human modules were significantly enriched for genetic variation associated with AD risk. This implies that microglial and oligodendrocytic ageing may contribute to AD risk, where genetic variants which alter the response of these cell-types to ageing in the human hippocampus may modulate the onset of AD 490 pathogenesis. While the influence of microglia on AD risk is well known<sup>53</sup>, the

relationship between oligodendrocytes and myelination on AD risk is less well understood. Although it has been previously suggested that individuals with white 493 matter abnormalities show a higher risk of dementia<sup>54</sup>, and disruption of the expression and epigenetic marks of oligodendrocytic genes is seen in AD and 495 ageing<sup>15,55–59</sup>.

We highlight new genes not previously reported to be associated with AD, and show that they may have a role in age-related responses. Although, we cannot discount the possibility that these modules are associated with AD due to the same genes being involved in the response to both Aβ-associated cellular damage during the AD process, and in the cellular response to ageing. The hub genes for these modules, and transcription factors whose targets are enriched within these modules, are putative drivers, and potential targets to influence these AD-related modules.

We identified gene expression networks that were significantly associated with age from different bulk and scRNA-seq datasets representing distinct cell-types and biological processes using wild-type mice to reduce the confounds of co-morbidities associated with human tissue. We find that common genetic variation associated with longevity is modestly enriched in genes expressed by homeostatic microglia. Collectively, our bulk and single-cell analyses suggest a new hypothesis whereby genes associated with longevity in the human population may be most active in homeostatic microglial processes, or may control how readily innate immune cells exit the homeostatic state, while genes associated with AD are involved in responses to substantial disturbances of CNS homeostasis, such as age-related myelin breakdown and amyloid pathology (Fig. 8). The microglial-expressed genes may

govern whether microglia can resolve the myelin turnover and facilitate healthy ageing, or whether microglia fail to repair myelin damage, leading to CNS dyshomeostasis and potentially then to AD. This two-hit hypothesis involving control of microglial homeostatic functions, and then activation of microglia to support oligodendrocyte function may underlie how ageing and AD are linked. Discovering these genes showing variation associated with age may allow us to predict 'physiological-age' versus 'chronological age' in the brain, and thus to better predict AD and other age-related diseases. These insights may also lead to intelligent design of new biomarkers to track disease progression and new mechanistic insights for drug development.

### Differences between human and mice age-related microglial responses

Many studies have reported differences in microglial responses to AD-associated features between mice and humans, with characterisation of human AD microglia 530 (HAM), and other related work<sup>41,60</sup>. Similarly, our preservation analysis showed only modest preservation of age-dependent microglial networks between human and mice. ARM/DAM are thought to be protective in mouse models of AD, thus the lack of the ARM/DAM profile at the end stages of disease could be a distinguishing factor for human AD. In our analysis we see a number of key genes are present in both the human and mouse age-dependent microglial network including AIF1, C3, CD33, CLEC7A, CTSS, CX3CR1, IRF8, LAPTM5, P2RY13, TLR3 and TREM2. Genes 537 unique to the mouse age-dependent microglial network included B2m, Cst7, Pik3cg and Ccl4, and also Il33 which is expressed mostly by oligodendrocytes. IL-33 has been shown to have beneficial effects on synaptic plasticity, microglial clearance and AD-associated pathology in rodent models<sup>61–63</sup>. In contrast, genes unique to the

human age-dependent microglial network included some familiar genes known to be involved or implicated in AD, including ABI3, C1QA-C, CSF1R, ITGAM, MRC1, MS4A6A, RUNX1, SAMSN1, SPI1 and TYROBP. An intriguing possibility is the stronger age-dependency of some of these genes in humans contribute to progression of AD. Our analysis of biological annotations associated with the age-dependent genes unique to either mouse or human, revealed that age-dependent genes unique to mouse were associated with antigen presentation involving MHC. In contrast, age-dependent genes unique to humans were associated with leukocyte activation, cytokine production and T cell activation. Recent studies have indicated that T cells expand in the brain during AD and ageing, and may contribute to disease progression<sup>64–68</sup>. Thus, microglial genes especially age-regulated in humans may contribute to ageing and AD, in part by recruitment and/or activation of other immune cells, including T cells.

# Human common gene-level variation associated with longevity is enriched in an age-dependent single-cell homeostatic microglial co-expression network

While there are clearly differences between human and mouse microglial responses to ageing, the separation of genes into microglial functions afforded by our co-expression analysis of single-cell mouse microglial transcriptomes, combined with our analysis of longevity associated genes, highlighted that homeostatic functions of innate immune cells may be a significant contributor to longevity. Potentially, the loss of these functions during ageing, possibly triggered in the hippocampus by microglial activation to respond to age-related demyelination, may disrupt brain homeostasis, ultimately leading to less healthy ageing and an earlier death. This is a novel suggestion, but is not totally surprising, as markers of neuronal damage are positively

566 associated with mortality in elderly individuals<sup>69</sup>, and microglia's homeostatic 567 functions maintain neuronal function and neurogenesis<sup>70–72</sup>. Additionally, by conducting this analysis and grouping co-expressed genes into modules enriched for associations to specific biological annotations and populations of microglia, we provide a resource for researchers to gain a preliminary idea of a potential function of their gene-of-interest, simply by looking up in which module it is expressed. As this approach was no doubt hampered by the sparse nature of scRNA-seq data, we foresee it to become even more capable to distinguish groups of co-expressed genes involved in similar cellular processes as technology improves.

We particularly highlight a potential role for microglia in mediating at least some of ATXN2 and FOXO3's impact on longevity, which requires further exploration. FOXO3 has previously been reported to augment microglial proliferation, activation, 579 and apoptotic injury<sup>73</sup>. Therefore, lower  $FOXO3$  levels could lead to longevity, as indicated by our TWAS of whole-blood samples, by reducing loss of homeostatic myeloid cells during ageing. To our knowledge, ATXN2 function has not been investigated in microglia, although it is expressed in both mouse (as shown by this 583 study) and human microglia (Myeloid Landscape dataset)<sup>41</sup>. Reduction of  $Atxn2$ expression extended the lifespan and decreased the pathology of a mouse model of 585 neurodegeneration<sup>74</sup>.

CASP8 is a protease with a well-known critical role in cell death mechanisms such as 588 inflammation, necroptosis and apoptosis<sup>75–77</sup>. CASP8 expression has been associated with several neurodegenerative disorders, in particular AD, Parkinson's disease, and 590 autoimmune disorders<sup>75,76,78,79</sup>. Several studies demonstrated that LPS primed

microglia promoted microglial proliferation, survival and pro-inflammation in a 592 CASP8-dependent manner, associated with neurotoxicity towards neurons<sup>75,76,80</sup>. CASP8 has been reported to mediate Aβ-induced neuronal apoptosis, leading to the 594 characteristic neuronal loss in  $AD^{78}$ . In a recent study, CASP8 was found to be active 595 in multiple sclerosis (MS) lesions<sup>79</sup>. Surprisingly, while microglial Casp8 ablation in experimental autoimmune encephalomyelitis mice didn't affect the course of disease, 597 myeloid  $Casp8$  ablation worsened the autoimmune demyelination, as CASP8 acts as a negative regulator of the RIPK1/RIPK3/IL-1β pathway. Furthermore, a study of skin fibroblasts showed CASP8 cleaved ATG3 and p63, controlling autophagy and 600 nutrient sensing, which are pathways known to be dysregulated in ageing<sup>81</sup>. This CASP8/AG3/p63 pathway has not been explored in other cell types, which would be beneficial for understanding the role of CASP8 in ageing. Finally, a decline in T cell numbers and impaired antibody production in B cells were observed in mice in the 604 absence of  $Casp8^{82}$ , emphasising its importance in immunity. These findings suggest a cell/tissue-specific role of CASP8 in the body. Our TWAS data indicate lower levels of CASP8 in the cortex and cerebellum are associated with longevity which may act by attenuating chronic neuroinflammation and cell death in the brain and thus, promote longevity. While we also saw in our TWAS data with whole blood the opposite effect to that in the cortex, where higher CASP8 levels were associated with longevity, suggesting that CASP8 may be beneficial for maintaining the innate and adaptive immune function of peripheral blood cells. It may be that the opposing effects seen for CASP8 in cortex versus whole blood could be a direct effect of CASP8 in longevity promotion in one cell type, followed by a secondary, indirect compensatory response in the other cell type.

### Oligodendrocyte function in ageing and AD

Interestingly, changes in the expression of microglial co-expression modules showed remarkable similarity between ageing and responses to demyelination in young mice. Combined with the predominant oligodendrocytic expression of the bulk mouse microglial module's hub genes, this indicates that microglial responses during ageing could be driven by age-related demyelination. Therefore, it may be the microglial response to age-related demyelination that disrupts their longevity-associated homeostatic networks. Similarly, HAMs seen in human AD patients, have similar transcriptional profiles to microglial populations detected in MS patients, suggesting the possibility that demyelination may be a common phenomenon in ageing, MS, and  $AD^{41}$ .

Early changes in myelination and oligodendrocytes have been identified with 629 AD<sup>58,59,83–85</sup>. Indeed, recent work shows that *APOE* status affects myelination and 630 oligodendrocyte function<sup>86,87</sup>. Myelin debris is lipid-rich and compacted, and so is difficult to digest by microglia. This may contribute to microglial dysfunction, brain ageing and neurodegeneration. In leukodystrophies (myelin degeneration), activated microglia collect in "nodules," providing further evidence of the importance of microglia in responding to changes in myelin and axon integrity. White matter-associated microglia have distinct transcriptional profiles, depend on TREM2 signalling and upregulate ARM-associated genes involved in lipid metabolism and 637 phagocytosis (such as *Apoe*, Cst7, Bm2 and Ctsb)<sup>13</sup>. This is consistent with the TREM2 receptor binding to a series of ligands related to myelin debris uptake including apolipoproteins and anionic lipids. In our age-dependent human transcriptome networks TREM2 was central in the microglial network, alongside

downstream mediators TYROBP and SYK and this age-dependent network was enriched with genetic variation associated with AD. Individuals with homozygous loss-of-function of TREM2 display Nasu-Hakola disease, where leukoencephalopathy is a prominent feature. Amongst our putative risk genes from the ageing-associated 645 TWAS analysis include EIF2B2, NPC1 and TUFM which show leukodystrophy as a feature in people inheriting mutations of these genes (Leukoencephalopathy with vanishing white matter, Niemann-Pick disease and combined oxidative phosphorylation deficiency 4, respectively). Thus, promoting myelin integrity and microglial activity to support remyelination is an emerging area of therapeutics for  $AD^{17,84,88}$ .

### Validation by subsequent GWAS studies

A recent GWAS representing the largest association study for dementia identified *ANKH*, GRN, PLEKHA1, SNX1 and UNC5CL as new genes of interest<sup>89</sup>, which validates our analysis here, as we also identify these genes as putative risk genes for AD, with a much smaller sample size than in the AD GWAS. We identified that the inorganic pyrophosphate transport regulator, ANKH, and PLEKHA1 were expressed by DAM/ARM cells. ANKH is a transmembrane protein involved in pyrophosphate  $(659)$  (PPi) and ATP efflux which inhibits excessive mineralization and calcification<sup>90</sup>, and is linked to altered mineralization of tissues, including calcification of the vasculature leading to atherosclerosis. Limited studies have investigated the role of ANKH in vivo, but one study addressing vascular calcification in a rat model reported that ANKH activity is suppressed by TNF-alpha-activated NF-κB in immune cells which promotes a pro-inflammatory signature, suggesting a role for this gene in regulating 665 inflammation associated with disease<sup>91</sup>. Furthermore, study of a consanguineous

family with a novel ANKH mutation showed mental retardation in combination with the expected ankylosis and soft tissues, and provided the first evidence of the 668 pathological effect of  $ANKH$  in the CNS<sup>92</sup>. Recent work has also shown strong association of ANKH genetic variation with cognitive change in people with normal 670 ageing and probable AD using fluorodeoxyglucose- $PET^{93}$ . GRN was confirmed to be 671 a risk gene for dementia<sup>89</sup>, and more specifically frontotemporal degeneration<sup>94</sup>. GRN was expressed by microglia transitioning to the DAM/ARM state in our analysis. GRN is of interest to the microglial community because loss-of-function mutations have been shown to cause excessive activation of microglia, showing generally 675 opposing effects to TREM2 loss-of-function mutations<sup>95</sup>. SNX1 is expressed at the highest level by oligodendrocytes. SNX1 is a member of the sorting nexin family (SNX) which is involved in endosomal protein sorting and its dysfunction has been 678 linked to neurodegenerative diseases including  $AD^{96}$ . UNC5CL was also part of the age-dependent oligodendrocyte network but is close to the TREM2 locus and so may 680 be linked to  $TREM2$  SNPs<sup>89</sup>.

#### Canonical genes involved in neurodegeneration are associated with longevity

Throughout these investigations we saw that many genes associated with different neurodegenerative conditions either showed genetic variation associated with lifespan, or were part of age-dependent co-expression modules, suggesting that these neurodegenerative genes may exert part of their effects in regulating disease in response to specific cellular processes during ageing. We saw that MAPT had genetic 688 association with longevity at the gene-level assessed by GWAS SNPs (gene-based  $p =$ 0.04), and was significant in our TWAS analysis showing that lower expression of MAPT in the cerebellum was associated with longevity (Supplementary Fig. 5).

PSEN1 is a hub gene in the human age-dependent oligodendrocyte network (Fig. 5). Mobp, whose human orthologue is a risk gene for tauopathy progressive supranuclear 693 palsy, corticobasal degeneration and amyotrophic lateral sclerosis $97-99$ , was a hub gene in the mouse age-dependent oligodendrocyte network (Fig. 1). HTT, which shows repeat expansions causing Huntington's disease, showed genome-wide significance in our TWAS analysis, with lower expression of HTT in the whole blood associated with longevity (Supplementary Fig. 5). Similarly, expansion of CAG trinucleotide repeats in the ATXN2 gene are associated with increased risk of amyotrophic lateral 699 sclerosis<sup>100</sup>, and  $ATXN2$  was a significant TWAS hit in our study. These findings suggest that common genetic variation in these genes, or their co-expression networks, may also modify lifespan through changes in gene expression between human individuals, in contrast to the familial mutations seen in genes such as MAPT and PSEN1 which alter the amino acid sequence and lead to the protein deposition that is seen in early onset neurodegeneration.

#### General immune system changes may govern whole organism ageing

The putative gene variants associated with longevity in this study, although identified by enrichment in the homeostatic microglial network of the brain, are expressed in 709 other immune cells including  $CD4^+$  T memory T<sub>REG</sub> cells, natural killer cells, 710 neutrophils, monocytes and macrophages $101-103$ . A possibility remains that these identified genes may affect the ageing of the brain and progression of AD by interaction of CNS-resident microglia with other immune cells associated with the blood-brain barrier or throughout the body. T cell changes in the brain that may 714 contribute to ageing and AD have been discussed above  $64-67$ . Putative ageing-associated genes include CASP8, FES, ZKSCAN5, JAM3, STAT3 and USP38, which

are expressed by multiple immune cells. It is also possible that the function of these genes in immune cells impact the ageing of the brain via intermediate tissues, such as 718 the vasculature, which has recently been shown to contribute to brain ageing<sup>104,105</sup>. The immediate next steps of this work are to investigate the array of homeostatic functions of these ageing-associated genes in microglia. Collectively the immune system changes described in our study are likely to contribute to the "Inflammageing" hypothesis of ageing, whereby chronic inflammatory processes promote the ageing of 723 multiple tissues<sup>68,106</sup>, including the brain.

In conclusion, we identify unbiased co-expression networks in the ageing brain that are enriched for genetic variation associated with AD or longevity to gain new insights into the cell types and cellular processes driving brain ageing and AD. We show that genetic risk for AD is enriched in age-dependent activated microglia and oligodendrocytes. In contrast, we show that genetic variation associated with longevity is enriched in homeostatic microglia. Thus genetic variants associated with longevity and AD both fall on microglia but controlling different and opposing states of their function (homeostatic versus activated). Understanding the function of these priority risk and hub genes may allow us to develop interventions to slow age-related brain decline and AD. These genetic networks driving ageing, AD and inflammageing may help to predict the physiological age of the brain and AD progression more accurately in individual people by generation of biomarker and genotyping assays.

#### Methods

#### Sample cohorts

AD: we used the publicly available GWAS summary statistics data from the International Genomics of Alzheimer's Projects (IGAP) from the stage 1 GWAS 742 meta-analysis of 21,982 AD cases and 41,944 cognitively normal controls<sup>21</sup>.

Ageing: we used the publicly available summary statistics data from European-ancestry GWAS data with overlapping ageing traits, incorporating three GWASs covering healthspan (300,477 individuals, of which 28.3% were not healthy), parental lifespan (1,012,240 parents, of which 60% were deceased), and longevity (defined by 11,262 individuals surviving to the 90th percentile of life, and 25,483 controls 749 whose age at death corresponds to the 60th survival percentile)<sup>10,11</sup>.

### Gene-based analysis

752 Gene-based testing was performed using MAGMA  $v1.08^{107}$  to obtain gene-based significance (p-values) using GWAS summary statistics. The gene-based approach we used summarizes the strength of the association of multiple adjacent SNPs restricted to individual gene boundaries (sequence between the first and last exons, including the introns), and so accounts for common and complex DNA variants associated with a particular trait, e.g. if longevity is conferred by several (semi) independent SNPs 758 within a locus, each with moderate effect sizes<sup>107,108</sup>. SNPs were assigned to genes based on the location obtained from the NCBI (no annotation window was added around the genes), and Phase 3 of 1,000 Genome build 37 was used as a reference panel. All required files can be downloaded from the software's website (https://ctg.cncr.nl/software/magma). Finally, the SNP-wise mean model was used for

the analysis. We report the gene-based p-values both before and after the FDR correction.

### RNA-seq data pre-processing

Transcripts per million (TPM) normalised bulk RNA-seq datasets generated from wild-type C57BL/6J mice (8-, 16-, 32-, and 72-weeks-of-age; data available from 769 Mouseac.org)<sup>24</sup>, and non-diseased human hippocampi (from 196 individuals; v8 TPM 770 counts downloaded from gtexportal.org/home/datasets)<sup>43</sup>, were filtered to remove genes with <5% variation between samples, or mean expression levels below 0.5 TPM in all experimental groups. As large differences in gene expression distributions between samples were detected in GTEx data, this data was quantile-quantile normalised using preprocessCore R package's normalize.quantiles function. These bulk RNA-seq datasets were then transformed by log2(normalised counts+1). Batch effects were analysed in bulk RNA-seq datasets by multidimensional scaling using the limma R package's plotMDS function to visualise sample clustering due to sequencing batch. Additionally, correlation of batch covariates to principle components of variation between samples, were identified using the swamp R 780 package's prince function and the CoExpNets R package's princePlot function<sup>23</sup>.

Bulk RNA-seq datasets generated from microglia isolated from the hippocampus of 783 aged and adult wild-type mice<sup>35</sup> (data available from publication), or the corpus callosum of mice treated for zero, 5-, or 12-weeks with a demyelinating cuprizone 785 diet<sup>40</sup> (data downloaded from GSO: GSE130627), were normalised using DeSeq2's 786 estimatesizefactors function<sup>109</sup>. Genes with an average detection level  $\leq 1.5$ normalised counts were removed.

Normalised bulk RNA-seq datasets generated from the hippocampi of wild-type mice 790 of different ages<sup>31-33</sup>, used to assess module preservation, were downloaded from Synapse accession syn20808171, GSO: GSE110741, and GSO: GSE61918, respectively. Genes with an average detection level <0.5 normalised counts or 793 between sample variation  $\leq 5\%$ , and samples detected as outliers by having p $\leq 0.05$ 794 result from the outliers R package's grubbs.test function were removed.

Raw counts generated by plate-based scRNA-seq of microglia isolated from the hippocampi of 3-, 6-, 12-, and 21-month-old wild-type mice (downloaded from 798 GSE127893; non-hippocampal and  $APP<sup>NL-G-F</sup>$  samples were removed)<sup>34</sup>, were filtered to remove cells which appeared either unhealthy (>5% of reads aligned to mitochondrial genes or <1500 transcripts or <1000 genes sequenced) or potential doublets (>3500 genes sequenced). Counts were then transformed by log2(normalised counts+1), and genes not detected in >98.5% of cells in all predefined clusters, or with between sample variation <4%, were removed. Batch effects were assessed by running downstream analysis and determining correlation of generated modules to sequencing plate.

As all datasets demonstrated batch effects, these were removed using limma's 808 removeBatchEffect function. The effects of trait(s)-of-interest were preserved using this function's design argument. This function's covariate argument was also used to remove the effects of confounding covariates, extraction batch, sequencing batch, post-mortem interval, sex, cause of death, and centre of origin, from the GTEx dataset.

#### 813 Co-expression network analysis

#### 814 Module Construction

815 Co-expression analysis was performed on pre-processed datasets using CoExpNets' 816 getDownstreamNetwork function. CoExpNets is an optimisation of the popular 817 WGCNA package<sup>22</sup>, which uses an additional k-means clustering step to reassign 818 genes to more appropriate modules, producing more biologically relevant and 819 reproducible modules<sup>23</sup>. Module eigengenes (ME), identified by CoExpNets were 820 correlated (Pearson's product moment correlation) to numeric traits of interest using 821 CoExpNets' corWithNumTraits function, or to categorical traits using the 822 corWithCatTraits function.

823

824 Biological annotation

Modules formed by co-expression analysis were assessed for enrichment of cell-type specific genes using CoExpNets' genAnnotationCellType function. Module enrichment for biological annotations was assessed using the Gprofiler2 R package's *gost* function<sup>44</sup>. The genes assigned to the module (ordered by correlation with the module eigengene), were input as the query argument and all genes expressed above 830 the expression threshold (TPM  $= 0.5$  for bulk RNA-seq datasets, and detection in  $\geq$ 2.5% of cells in any cell cluster for scRNA-seq datasets), were used as the custom background. Predicted annotations were excluded, and p-values were Bonferroni 833 corrected. Module expression by age was assessed by two-tailed Student's t-test of the mean expression of the module's 100 most central genes (genes with highest 835 correlation with the module eigengene) in the processed O'Neil *et al.* (2018) dataset<sup>35</sup>, while module expression in cuprizone treatment groups was assessed by one-way ANOVA followed by the pairwise comparison of cuprizone diet timepoints to control



Module preservation

Module preservation between our networks was calculated in pre-processed datasets described above, using CoExpNets' preservationoneway function. Control module size was set to 400. This returned preservation statistics calculated by the WGCNA 845 modulePreservation function<sup>110</sup>, of which z.summary (summary of other preservation 846 statistics), was reported unless the two sub-measures of preservation (z.connectivity and z.density) differed significantly. Comparison between human and mouse datasets was preceded by conversion of gene symbols to orthologues using the biomaRt R 849 . package<sup>111</sup>. Module eigengenes were detected in query datasets using CoExpNets getNetworkEigengenes function.

#### Pseudotime analysis

853 We used the Monocle 2 R package to infer single-cell transcriptional trajectories<sup>38,112</sup>. based on the expression of genes significantly differentially expressed (qval < 0.025) 855 between cell clusters identified in Ref<sup>34</sup>.

#### Enrichment analyses of identified overlapping genes

Enrichment analyses were performed by comparing the number of overlapping genes showing genetic association with AD or longevity derived from summary statistics 860 from Kunkle *et al.*  $(2019)^{21}$ , and Timmers *et al.*  $(2020)^{10}$ , respectively, to our transcriptome module gene-sets with gene-sets randomly bootstrapped (Ninterations=100,000), from genes reliably expressed in the bulk RNA-seq (>0.5

TPM in any experimental group), and scRNA-seq datasets (expressed in >2.5% cells 864 from any cluster). The random gene sets were matched to the gene sets of interest by: a) the number of genes in a set, and b) the numbers of independent SNPs per gene. The latter was estimated by MAGMA software as the number of principal components of the SNP data matrix of the gene, pruning away principal components with very small eigenvalues ensuring that only 0.1% of the variance in the SNP data matrix is pruned away. The enrichment analyses p-values (bootstrap p-values in the text) do not require correction for multiple testing because the different age-associated 871 gene modules were pre-selected from different transcriptome datasets *(i.e.* mouse versus human, bulk versus single-cell RNA-seq).

873

### 874 Transcriptome-wise association study (TWAS)

875 Expression weights were used in TWAS for autosomal chromosomes and excluding 876 the MHC region, with the longevity summary statistics<sup>10</sup>, using the R script 877 FUSION.assoc test.R from the FUSION software<sup>113</sup>. The TWAS weights were 878 downloaded from the FUSION website (GTEX7 Brain (13 tissues), GTEX7 Whole 879 blood)<sup>43,49</sup>, YFS blood<sup>50</sup>, NTR blood<sup>51</sup>, and for all monocytes in the dataset produced 880 by Fairfax et al.  $(2014)^{48}$  (samples: CD14, LPS2, LPS24 and IFN-gamma), 881 downloaded from https://github.com/janetcharwood/MONOCYTE\_TWAS (see 882 Harwood *et al.*  $(2021)^{20}$  for details). Bonferroni correction for the number of genes 883 analysed in each tissue was used to determine significance of TWAS associations. 884 Plink v1.9 was used for SNP quality-control analysis, and MAGMA (v1.08) to obtain 885 gene-wide p-values, and Logistic regression was performed in R.

886

### Acknowledgements



freely available via GitHub. The data used for this study are publicly available for

non-commercial research purposes, accession numbers are given in Methods.

#### References

- 904 1. Wahl, D. et al. Nutritional strategies to optimise cognitive function in the aging brain. Ageing Res. Rev. 31, 80–92 (2016).
- 2. Murman, D. L. The Impact of Age on Cognition. Semin. Hear. 36, 111–121 (2015).
- 3. Fan, X., Wheatley, E. G. & Villeda, S. A. Mechanisms of Hippocampal Aging and the Potential for Rejuvenation. Annu. Rev. Neurosci. 40, 251–272 (2017).
- 910 4. Volianskis, A. et al. Long-term potentiation and the role of N-methyl-D-
- 911 aspartate receptors. Brain Res. 1621, 5-16 (2015).
- 5. Partridge, L., Fuentealba, M. & Kennedy, B. K. The quest to slow ageing 913 through drug discovery. Nature Reviews Drug Discovery 19, 513–532 (2020).
- 6. Middeldorp, J. et al. Preclinical assessment of young blood plasma for Alzheimer disease. JAMA Neurol. 73, 1325–1333 (2016).
- 7. Salih, D. A. & Brunet, A. FoxO transcription factors in the maintenance of cellular homeostasis during aging. Current Opinion in Cell Biology 20, 126– 136 (2008).
- 8. Askew, K. et al. Coupled Proliferation and Apoptosis Maintain the Rapid 920 Turnover of Microglia in the Adult Brain. *Cell Rep.* **18**, 391–405 (2017).
- 9. Udeochu, J. C., Shea, J. M. & Villeda, S. A. Microglia communication: Parallels between aging and Alzheimer's disease. Clin. Exp. Neuroimmunol. 7, 114–125 (2016).
- 10. Timmers, P. R. H. J., Wilson, J. F., Joshi, P. K. & Deelen, J. Multivariate genomic scan implicates novel loci and haem metabolism in human ageing. Nat. Commun. 11, 1–10 (2020).
- 927 11. Deelen, J. et al. A meta-analysis of genome-wide association studies identifies

- 928 multiple longevity genes. Nat. Commun. 10, 1–14 (2019).
- 929 12. Safaiyan, S. et al. Age-related myelin degradation burdens the clearance 930 function of microglia during aging. Nat. Neurosci. 19, 995–998 (2016).
- 931 13. Safaiyan, S. et al. White matter aging drives microglial diversity. Neuron 109, 932 1100-1117.e10 (2021).
- 933 14. Mahmood, A. & Miron, V. E. Microglia as therapeutic targets for central 934 nervous system remyelination. Curr. Opin. Pharmacol. 63, 102188 (2022).
- 935 15. White, C. W. 3rd, Pratt, K. & Villeda, S. A. OPCs on a Diet: A Youthful 936 Serving of Remyelination. Cell Metab. 30, 1004–1006 (2019).
- 937 16. Lloyd, A. F. et al. Central nervous system regeneration is driven by microglia 938 necroptosis and repopulation. Nat. Neurosci. 22, 1046–1052 (2019).
- 939 17. McNamara, N. B. et al. Microglia regulate central nervous system myelin 940 growth and integrity. *Nature* **613**, 120–129 (2023).
- 941 18. Depp, C. et al. Ageing-associated myelin dysfunction drives amyloid 942 deposition in mouse models of Alzheimer's disease. bioRxiv 943 2021.07.31.454562 (2021). doi:10.1101/2021.07.31.454562.
- 944 19. Yassa, M. A. et al. Pattern separation deficits associated with increased 945 hippocampal CA3 and dentate gyrus activity in nondemented older adults. 946 *Hippocampus* **21**, 968–979 (2011).
- 947 20. Harwood, J. C. et al. Defining functional variants associated with Alzheimer's 948 disease in the induced immune response. *Brain Commun*. 3, fcab083 (2021).
- 949 21. Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer's disease
- 950 identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. 951 *Nat. Genet.* 51, 414–430 (2019).
- 952 22. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation

- 953 network analysis. BMC Bioinformatics 9, 559 (2008).
- 954 23. Botía, J. A. *et al.* An additional k-means clustering step improves the biological
- 955 features of WGCNA gene co-expression networks. BMC Syst. Biol. 11, 47 956 (2017).
- 957 24. Salih, D. A. et al. Genetic variability in response to amyloid beta deposition 958 influences Alzheimer's disease risk. Brain Commun. 1, fcz022 (2019).
- 959 25. Xue, Z. *et al.* Genetic programs in human and mouse early embryos revealed 960 by single-cell RNA sequencing. Nature 500, 593–597 (2013).
- 961 26. van Dam, S., Võsa, U., van der Graaf, A., Franke, L. & de Magalhães, J. P. 962 Gene co-expression analysis for functional classification and gene–disease 963 predictions. Brief. Bioinform. 19, 575–592 (2018).
- 964 27. Ogrodnik, M. et al. Whole-body senescent cell clearance alleviates age-related 965 brain inflammation and cognitive impairment in mice. Aging Cell 20, e13296 966 (2021).
- 967 28. Butler, C. A. *et al.* Microglial phagocytosis of neurons in neurodegeneration, 968 and its regulation. J. Neurochem. 158, 621–639 (2021).
- 969 29. He, D. et al. Disruption of the IL-33-ST2-AKT signaling axis impairs 970 neurodevelopment by inhibiting microglial metabolic adaptation and 971 phagocytic function. *Immunity* **55**, 159-173.e9 (2022).
- 972 30. Nguyen, P. T. et al. Microglial Remodeling of the Extracellular Matrix 973 Promotes Synapse Plasticity. Cell 182, 388-403.e15 (2020).
- 974 31. Zhao, N. et al. Alzheimer's Risk Factors Age, APOE Genotype, and Sex 975 Drive Distinct Molecular Pathways. Neuron 106, 727-742.e6 (2020).
- 976 32. Sierksma, A. et al. Novel Alzheimer risk genes determine the microglia 977 response to amyloid-β but not to TAU pathology. *EMBO Mol. Med.* 12, e10606

- 978 (2020).
- 979 33. Stilling, R. M. et al. De-regulation of gene expression and alternative splicing 980 affects distinct cellular pathways in the aging hippocampus. Front. Cell. 981 Neurosci. **8**, 373 (2014).
- 982 34. Sala Frigerio, C. et al. The Major Risk Factors for Alzheimer's Disease: Age, 983 Sex, and Genes Modulate the Microglia Response to Aβ Plaques. Cell Rep. 27, 984 1293-1306.e6 (2019).
- 985 35. O'Neil, S. M., Witcher, K. G., McKim, D. B. & Godbout, J. P. Forced turnover 986 of aged microglia induces an intermediate phenotype but does not rebalance 987 CNS environmental cues driving priming to immune challenge. Acta 988 Neuropathol. Commun. 6, 129 (2018).
- 989 36. Keren-Shaul, H. et al. A Unique Microglia Type Associated with Restricting 990 Development of Alzheimer's Disease. Cell 169, 1276-1290.e17 (2017).
- 991 37. Qiu, X. et al. Reversed graph embedding resolves complex single-cell 992 trajectories. Nat. Methods 14, 979–982 (2017).
- 993 38. Trapnell, C. et al. The dynamics and regulators of cell fate decisions are 994 revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381– 995 386 (2014).
- 996 39. Hill, R. A., Li, A. M. & Grutzendler, J. Lifelong cortical myelin plasticity and 997 age-related degeneration in the live mammalian brain. Nat. Neurosci. 21, 683– 998 695 (2018).
- 999 40. Nugent, A. A. et al. TREM2 Regulates Microglial Cholesterol Metabolism 1000 upon Chronic Phagocytic Challenge. Neuron 105, 837-854.e9 (2020).
- 1001 41. Srinivasan, K. et al. Alzheimer's Patient Microglia Exhibit Enhanced Aging 1002 and Unique Transcriptional Activation. Cell Rep. 31, 107843 (2020).

- 42. Galatro, T. F. et al. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nat. Neurosci. 20, 1162–1171 (2017).
- 43. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648–660 (2015).
- 44. Kolberg, L., Raudvere, U., Kuzmin, I., Vilo, J. & Peterson, H. gprofiler2 -- an R package for gene list functional enrichment analysis and namespace
- conversion toolset g:Profiler [version 2; peer review: 2 approved]. F1000Research 9(ELIXIR), 709 (2020).
- 45. Sanese, P., Forte, G., Disciglio, V., Grossi, V. & Simone, C. FOXO3 on the 1013 Road to Longevity: Lessons From SNPs and Chromatin Hubs. Comput. Struct. Biotechnol. J. 17, 737–745 (2019).
- 1015 46. Imbert, G. *et al.* Cloning of the gene for spinocerebellar ataxia 2 reveals a locus 1016 with high sensitivity to expanded CAG/glutamine repeats. Nat. Genet. 14, 285– 291 (1996).
- 1018 47. Fritsch, M. et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature 575, 683–687 (2019).
- 1020 48. Fairfax, B. P. et al. Innate immune activity conditions the effect of regulatory 1021 variants upon monocyte gene expression. Science 343, 1246949 (2014).
- 1022 49. Aguet, F. et al. The GTEx Consortium atlas of genetic regulatory effects across human tissues. bioRxiv 787903 (2019). doi:10.1101/787903.
- 1024 50. Raitakari, O. T. et al. Cohort profile: the cardiovascular risk in Young Finns Study. Int. J. Epidemiol. 37, 1220–1226 (2008).
- 51. Willemsen, G. et al. The Netherlands Twin Register biobank: a resource for genetic epidemiological studies. Twin Res. Hum. Genet. Off. J. Int. Soc. Twin

- *Stud.* 13, 231–245 (2010).
- 52. Liu, C.-C., Liu, C.-C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature reviews. Neurology 9, 106–118 (2013).
- 53. Sierksma, A., Escott-Price, V. & De Strooper, B. Translating genetic risk of Alzheimer's disease into mechanistic insight and drug targets. Science 370, 61–66 (2020).
- 54. Prins, N. D. & Scheltens, P. White matter hyperintensities, cognitive impairment and dementia: An update. Nature Reviews Neurology 11, 157–165 (2015).
- 55. Murphy, K. B., Nott, A. & Marzi, S. J. CHAS, a deconvolution tool, infers cell type-specific signatures in bulk brain histone acetylation studies of brain disorders. bioRxiv 2021.09.06.459142 (2021). doi:10.1101/2021.09.06.459142.
- 1041 56. Saito, E. R. *et al.* Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression. Alzheimers. Dement. 17, 1474–1486 (2021).
- 57. Murthy, M. et al. Epigenetic age acceleration is associated with oligodendrocyte proportions in MSA and control brain tissue. Neuropathol. Appl. Neurobiol. 49, e12872 (2023).
- 1046 58. Vanzulli, I. et al. Disruption of oligodendrocyte progenitor cells is an early sign of pathology in the triple transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 94, 130–139 (2020).
- 59. Chacon-De-La-Rocha, I. et al. Accelerated Dystrophy and Decay of Oligodendrocyte Precursor Cells in the APP/PS1 Model of Alzheimer's-Like Pathology. Front. Cell. Neurosci. 14, 575082 (2020).
- 1052 60. Gosselin, D. et al. An environment-dependent transcriptional network specifies

- 1053 human microglia identity. Science 356, (2017).
- 61. Wang, Y. et al. Astrocyte-secreted IL-33 mediates homeostatic synaptic 1055 plasticity in the adult hippocampus. Proc. Natl. Acad. Sci. U. S. A. 118, e2020810118 (2021).
- 62. Lau, S.-F. et al. IL-33-PU.1 Transcriptome Reprogramming Drives Functional State Transition and Clearance Activity of Microglia in Alzheimer's Disease.
- Cell Rep. 31, 107530 (2020).
- 63. Fu, A. K. Y. et al. IL-33 ameliorates Alzheimer's disease-like pathology and 1061 cognitive decline. *Proc. Natl. Acad. Sci. U. S. A.* **113**, E2705-13 (2016).
- 1062 64. Gate, D. et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease. Nature 577, 399–404 (2020).
- 1064 65. Lemaitre, P. et al. Molecular and cognitive signatures of ageing partially restored through synthetic delivery of IL2 to the brain. bioRxiv 2022.03.01.482519 (2022) doi:10.1101/2022.03.01.482519.
- 1067 66. Yshii, L. et al. The AppNL-G-F mouse model of Alzheimer's disease is refractory to regulatory T cell treatment. bioRxiv 2022.03.11.483903 (2022).
- doi:10.1101/2022.03.11.483903.
- 1070 67. Kaya, T. et al. CD8+ T cells induce interferon-responsive oligodendrocytes and microglia in white matter aging. Nat. Neurosci. 25, 1446–1457 (2022).
- 68. Borgoni, S., Kudryashova, K. S., Burka, K. & de Magalhães, J. P. Targeting immune dysfunction in aging. Ageing Res. Rev. 70, 101410 (2021).
- 69. Rübsamen, N. et al. Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population—an analysis from the MEMO study. BMC Med. 19, 38 (2021).
- 1077 70. Rogers, J. T. et al. CX3CR1 deficiency leads to impairment of hippocampal

- cognitive function and synaptic plasticity. J. Neurosci. 31, 16241–16250 (2011).
- 71. Costello, D. A. et al. Long term potentiation is impaired in membrane glycoprotein CD200-deficient mice: A role for toll-like receptor activation. J.
- Biol. Chem. 286, 34722–34732 (2011).
- 72. Bachstetter, A. D. et al. Fractalkine and CX 3CR1 regulate hippocampal neurogenesis in adult and aged rats. Neurobiol. Aging 32, 2030–2044 (2011).
- 73. Shang, Y., Chong, Z., Hou, J. & Maiese, K. The Forkhead Transcription Factor
- FOXO3a Controls Microglial Inflammatory Activation and Eventual Apoptotic
- 1087 Injury through Caspase 3. Curr. Neurovasc. Res. 6, 20–31 (2009).
- 1088 74. Becker, L. A. et al. Therapeutic reduction of ataxin-2 extends lifespan and 1089 reduces pathology in TDP-43 mice. Nature 544, 367–371 (2017).
- 1090 75. Burguillos, M. A. *et al.* Caspase signalling controls microglia activation and 1091 neurotoxicity. *Nature* **472**, 319–324 (2011).
- 76. Zhang, C.-J. et al. TLR-stimulated IRAKM activates caspase-8 inflammasome in microglia and promotes neuroinflammation. J. Clin. Invest. 128, 5399–5412 (2018).
- 77. Orning, P. & Lien, E. Multiple roles of caspase-8 in cell death, inflammation, and innate immunity. J. Leukoc. Biol. 109, 121–141 (2021).
- 78. Wei, W., Norton, D. D., Wang, X. & Kusiak, J. W. Abeta 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain 125, 2036–2043 (2002).
- 79. Kim, S., Lu, H. C., Steelman, A. J. & Li, J. Myeloid caspase-8 restricts RIPK3- dependent proinflammatory IL-1β production and CD4 T cell activation in autoimmune demyelination. Proc. Natl. Acad. Sci. U. S. A. 119, e2117636119

- (2022).
- 80. Xu, S., Zhang, H., Yang, X., Qian, Y. & Xiao, Q. Inhibition of cathepsin L
- alleviates the microglia-mediated neuroinflammatory responses through caspase-8 and NF-κB pathways. Neurobiol. Aging 62, 159–167 (2018).
- 81. Sanchez-Garrido, J., Sancho-Shimizu, V. & Shenoy, A. R. Regulated proteolysis of p62/SQSTM1 enables differential control of autophagy and 1109 nutrient sensing. Sci. Signal. 11, eaat 6903 (2018).
- 1110 82. Lemmers, B. et al. Essential role for caspase-8 in Toll-like receptors and NFkappaB signaling. J. Biol. Chem. 282, 7416–7423 (2007).
- 83. Bouhrara, M. et al. Evidence of demyelination in mild cognitive impairment and dementia using a direct and specific magnetic resonance imaging measure 1114 of myelin content. Alzheimer's Dement. 14, 998-1004 (2018).
- 1115 84. Chen, J.-F. et al. Enhancing myelin renewal reverses cognitive dysfunction in a murine model of Alzheimer's disease. Neuron 109, 2292-2307.e5 (2021).
- 1117 85. Sadick, J. S. et al. Astrocytes and oligodendrocytes undergo subtype-specific transcriptional changes in Alzheimer's disease. Neuron 110, 1788-1805.e10 (2022).
- 86. Cheng, G. W.-Y. et al. Apolipoprotein E ε4 Mediates Myelin Breakdown by Targeting Oligodendrocytes in Sporadic Alzheimer Disease. J. Neuropathol. Exp. Neurol. 81, 717–730 (2022).
- 87. Blanchard, J. W. et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature 611, 769–779 (2022).
- 88. Nasrabady, S. E., Rizvi, B., Goldman, J. E. & Brickman, A. M. White matter 1126 changes in Alzheimer's disease: a focus on myelin and oligodendrocytes. Acta Neuropathol. Commun. 6, 22 (2018).

- 1128 89. Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer's 1129 disease and related dementias. Nat. Genet. 54, 412–436 (2022).
- 1130 90. Ho, A. M., Johnson, M. D. & Kingsley, D. M. Role of the mouse ank gene in 1131 control of tissue calcification and arthritis. Science 289, 265–270 (2000).
- 1132 91. Zhao, G. et al. Activation of nuclear factor-kappa B accelerates vascular 1133 calcification by inhibiting ankylosis protein homolog expression. Kidney Int. 1134 82, 34–44 (2012).
- 1135 92. Morava, E. et al. Autosomal recessive mental retardation, deafness, ankylosis, 1136 and mild hypophosphatemia associated with a novel ANKH mutation in a 1137 consanguineous family. J. Clin. Endocrinol. Metab. 96, E189—98 (2011).
- 1138 93. Nugent, S., Potvin, O., Cunnane, S. C., Chen, T.-H. & Duchesne, S.
- 1139 Associating Type 2 Diabetes Risk Factor Genes and FDG-PET Brain 1140 Metabolism in Normal Aging and Alzheimer's Disease. Front. Aging 1141 Neurosci. 12, 580633 (2020).
- 1142 94. Baker, M. et al. Mutations in progranulin cause tau-negative frontotemporal 1143 dementia linked to chromosome 17. Nature 442, 916–919 (2006).
- 1144 95. Götzl, J. K. et al. Opposite microglial activation stages upon loss of PGRN or 1145 TREM2 result in reduced cerebral glucose metabolism. *EMBO Mol. Med.* 11, 1146 e9711 (2019).
- 1147 96. Zhang, H. et al. The Retromer Complex and Sorting Nexins in 1148 Neurodegenerative Diseases. Front. Aging Neurosci. 10, 79 (2018).
- 1149 97. Höglinger, G. U. et al. Identification of common variants influencing risk of 1150 the tauopathy progressive supranuclear palsy. Nat. Genet. 43, 699–705 (2011).
- 1151 98. Kouri, N. et al. Genome-wide association study of corticobasal degeneration 1152 identifies risk variants shared with progressive supranuclear palsy. Nat.

- 1153 Commun. 6, 7247 (2015).
- 1154 99. van Rheenen, W. et al. Genome-wide association analyses identify new risk
- 1155 variants and the genetic architecture of amyotrophic lateral sclerosis. Nat.
- 1156 Genet. **48**, 1043-1048 (2016).
- 1157 100. Sproviero, W. et al. ATXN2 trinucleotide repeat length correlates with risk of 1158 ALS. Neurobiol. Aging 51, 178.e1-178.e9 (2017).
- 1159 101. Schmiedel, B. J. et al. Impact of Genetic Polymorphisms on Human Immune 1160 Cell Gene Expression. Cell 175, 1701-1715.e16 (2018).
- 1161 102. Schmiedel, B. J. et al. COVID-19 genetic risk variants are associated with 1162 expression of multiple genes in diverse immune cell types. Nat. Commun. 12, 1163 6760 (2021).
- 1164 103. Lavin, Y. et al. Tissue-resident macrophage enhancer landscapes are shaped by 1165 the local microenvironment. *Cell* 159, 1312–1326 (2014).
- 1166 104. Francis, C. M. et al. Genome-wide associations of aortic distensibility suggest 1167 causality for aortic aneurysms and brain white matter hyperintensities. Nat. 1168 Commun. 13, 4505 (2022).
- 1169 105. Wagen, A. Z. et al. Life course, genetic, and neuropathological associations
- 1170 with brain age in the 1946 British Birth Cohort: a population-based study.
- 1171 Lancet Heal. Longev. 3, e607-e616 (2022). doi:https://doi.org/10.1016/S2666- 1172 7568(22)00167-2.
- 1173 106. de Magalhães, J. P. & Passos, J. F. Stress, cell senescence and organismal 1174 ageing. Mech. Ageing Dev. 170, 2–9 (2018).
- 1175 107. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: 1176 generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 11, 1177 e1004219 (2015).

- 1178 108. Escott-Price, V. et al. Gene-Wide Analysis Detects Two New Susceptibility 1179 Genes for Alzheimer's Disease. *PLoS One* 9, e94661 (2014).
- 1180 109. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and 1181 dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
- 1182 110. Langfelder, P., Luo, R., Oldham, M. C. & Horvath, S. Is my network module 1183 preserved and reproducible? *PLoS Comput. Biol.* 7, e1001057 (2011).
- 1184 111. Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for
- 1185 the integration of genomic datasets with the R/Bioconductor package biomaRt.
- 1186 *Nat. Protoc.* 4, 1184–1191 (2009).
- 1187 112. Qiu, X. et al. Single-cell mRNA quantification and differential analysis with 1188 Census. Nat. Methods 14, 309–315 (2017).
- 1189 113. Gusev, A. et al. Integrative approaches for large-scale transcriptome-wide 1190 association studies. Nat. Genet. **48**, 245–252 (2016).



1192

1193

1194 Table 1. Test of enrichment of age-dependent gene modules with genes variants associated with Alzheimer's disease from GWAS of

1195 Kunkle et al. (2019)<sup>21</sup>. Gene modules from mouse hippocampus bulk RNA-seq (Fig. 1), mouse hippocampus scRNA-seq (Fig. 2, 3), and human 1196 hippocampus bulk RNA-seq (Fig. 5). ARM, activated response microglia. HM2, homeostatic microglial subcluster 2.



1198<br>1199

Table 2. Test of enrichment of age-dependent gene modules with genes variants associated with ageing from GWAS of Timmers et al. 1200 (2020)<sup>10</sup>. Gene modules from mouse hippocampus bulk RNA-seq (Fig. 1), mouse hippocampus scRNA-seq (Fig. 2, 3), and human hippocampus 1201 bulk RNA-seq (Fig. 5). ARM, activated response microglia. HM2, homeostatic microglial subcluster 2.

1202



Figure 1. Gene co-expression modules enriched for microglial and oligodendrocytic genes are significantly associated with age in the mouse hippocampus. A) Co-expression analysis of bulk RNA-seq of the mouse hippocampus produced eight gene modules with significant correlation to age using 1210 our Mouseac data<sup>24</sup>. Pearson's product-moment correlation with age, value given in 1211 each cell where  $R^2 > 0.4$ , \*\* p < 0.01, \*\*\* p < 0.001. No module has a significant association with either sequencing batch or lane, validating our batch correction strategy. B) Cell-type enrichment analysis reveals a significant enrichment of microglial genes in the microglial module, oligodendrocyte genes in the oligodendrocytic module, and dopaminergic neuron genes in the brown module. \* 1216 p<0.05, \*\* p <0.01, \*\*\* p < 0.001. C) Network plot of the 151 most connected genes in the microglial module (left). Hub genes are shown in red. Biological annotations (right). D) Network plot of the 152 most connected genes in the oligodendrocytic module (left). Hub genes are shown in red. Biological annotations (right). Full networks given in Supplementary Table 10 and 11.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.03.30.23287975;](https://doi.org/10.1101/2023.03.30.23287975) this version posted April 3, 2023. The copyright holder for this preprint



C

D



#### **Mouse microglial**

Enrichment terms microglial module







Hapin2 Cempb Rom1 Cm4593 Scd2 Dock5 Pla2g16 Plxnb3 Aspa 24933413G19Rik Trim36<br>
Dusp16 Cams1 Cyp27a1 Athgap23 Npc1 Shroom3 Phidb1 Gm13293<br>
Mob3b Hitlart Schnift Schnift Schnift Schnift Schnift<br>
The Second World Adams4 Tribl CO30029H02RIK<br>
Acam D7Ertd443eMog Bcast Tmil JMcam DTErid443sMg91 Boast JTmem88b Mbp Tip2 Rab31 JEvi2a Micall1<br>
Tmem125 Antiget10 Glip JEnpp4 Pri18<br>
SIC48a1 Sings Sesset Corp Pri18<br>
OCIsz Sic48a1 Sings Class Corp Print Sexuel Sesset Corp Print Sexuel Plan Class Cers2 Plipp2 Dec Duxbl3 Fa2h Dent Stpr5 Cent 150str Pist<br>
2011 Cers2 Plipp2 Dec Duxbl3 Fa2h Dollar 11 Celx19 JFpp3 Demtrase Galpt Spsbf1 Psatt<br>
2011 Cers2 Plipp2 Dec5a Ninj2 JGng11 JFpp3 Demt2328 Gpr37 Effid1<br>
26 Cers2 Pli  $Spg20$ Opalin Tyn<sub>2</sub> Clecsa Ninj2 Core<br>
14 Jugi3 Gpr62 Erbb3 Plma Obindd2<br>
1<sub>4</sub> J<sub>Lgi3</sub> Gpr62 Erbb3 Clic4 Plip<br>
Drap1 Sic44a1 Gjc2 Odpr Spg20<br>Carhsp1 9228<br>
Lpart Ado Thraip6<br>
1611 Rhog Kcng4  $Man<sup>2</sup>$ Gm35611

**Mouse oligodendrocytic** 

# **Figure 1**



- 
- 



**Figure 2** 



### Figure 3. Gene co-expression networks from microglia analysed by scRNA-seq

- associated with ageing. The genetic networks from microglial cells isolated from
- 1319 wild-type mice at 3, 6, 12 and 21 months-of-age analysed by scRNA-seq<sup>34</sup>. Network
- 1320 plot of the 45 most connected genes in the ARM-associated (A), interferon (B), HM2-
- associated (C), and phagolysosomal (D), modules. Green nodes represent genes, edge
- lines represent co-expression connections, and the central large red nodes are the hub
- genes. Full networks given in Supplementary Table 12, 13, 14 and 15.
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 





**HM2-associated module** 

Phagolysosomal module

 $Cd81$ 

 $C1qb$ 

 $\sum$ Trem2

 $C1q$ a

 $F<sub>cgr3</sub>$ 

Ctsd

 $C$ ctsl

 $\bigcup$  Hexa

 $\bigcirc$  Grn

 $O<sub>CG9</sub>$ 

 $\bigcirc$  Ctsz

**OD**dost

Serpine<sub>2</sub>

 $Cd53$ 

Abhd12

 $\bigcirc$ Ctsa

 $\bigcup$  Itm2c

 $Cvba$ 

 $\bigcirc$  Ctsb

 $C1qc$ 

 $O<sub>creq</sub>$ 

 $\bigcirc$  Bsg

 $Q$ Trf

 $\bigcirc$ Tcn2

 $Tmbim6$ 

Actb

 $T$ mem $50a$ 

 $OCH1$ 

 $Gapdh$ 

 $O_{Lag3}$ 

 $\bigcirc$  Actg1

**Figure 3** 

#### Figure 4. Gene co-expression network changes in microglia isolated from mice

- 1367 treated with cuprizone and analysed using scRNA-seq. A) Preservation analysis of
- age-related modules in a dataset generated by scRNA-seq of microglia isolated from
- the corpus callosum of 9-11 month old WT mice fed a control or demyelinating
- 1370 cuprizone diet for 5- or 12-weeks<sup>40</sup>. Control module represents results for randomly
- chosen genes of a similar module size. B-F) Comparison of expression of the 100
- most central genes (as a proxy of module expression) from the ARM-associated (B),
- interferon (C), ribosomal (D), HM2-associated (E), HM1-associated (F), and TGF-β
- (G) modules in microglia isolated from the corpus callosum fed a control diet or a
- 1375 demyelinating cuprizone diet for 5- or 12-weeks and profiled by bulk RNA-seq<sup>40</sup>.

- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 





It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.03.30.23287975;](https://doi.org/10.1101/2023.03.30.23287975) this version posted April 3, 2023. The copyright holder for this preprint



D

# **Preservation of GTEx hippocampus** in Mouseac



Module Size in Query Dataset

# **Preservation of Mouseac in GTEx** hippocampus



# **Figure 5**





Figure 6





**Figure 7** 





# Figure 8